Back to top
more

ADC Therapeutics (ADCT)

(Delayed Data from NYSE)

$4.34 USD

4.34
322,939

-0.10 (-2.25%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $4.34 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for ADCT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for ADC Therapeutics SA falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 279 326 467 439 116
Receivables 25 73 30 0 0
Notes Receivable 0 0 0 0 0
Inventories 16 19 11 0 0
Other Current Assets 16 28 17 11 7
Total Current Assets 336 446 525 450 123
Net Property & Equipment 6 3 4 2 1
Investments & Advances 2 31 41 48 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 27 26 0 0
Intangibles 0 14 14 10 8
Deposits & Other Assets 1 1 1 0 0
Total Assets 355 529 618 514 138
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 16 12 12 5 3
Current Portion Long-Term Debt 0 12 7 4 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 51 0 0 0 15
Income Taxes Payable 0 0 4 0 0
Other Current Liabilities 0 73 51 30 0
Total Current Liabilities 68 99 74 40 20
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 125 108 0
Long-Term Debt 113 97 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 312 238 246 27 3
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 503 440 452 178 27
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 7 7 6 6 4
Capital Surplus 1,181 1,007 982 981 550
Retained Earnings -1,335 -1,081 -925 -695 -449
Other Equity 0 155 103 43 6
Treasury Stock 1 1 0 0 0
Total Shareholder's Equity -148 89 166 336 111
Total Liabilities & Shareholder's Equity 355 529 618 514 138
Total Common Equity -148 89 166 336 111
Shares Outstanding 76.80 76.80 76.80 68.80 NA
Book Value Per Share -1.93 1.16 2.16 4.88 0.00

Fiscal Year End for ADC Therapeutics SA falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 279 310 348 311
Receivables NA 25 21 24 24
Notes Receivable NA 0 0 0 0
Inventories NA 16 23 19 18
Other Current Assets NA 16 21 22 27
Total Current Assets NA 336 376 413 380
Net Property & Equipment NA 6 5 5 4
Investments & Advances NA 2 27 28 30
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 35 35 28
Intangibles NA 0 12 14 14
Deposits & Other Assets NA 1 1 1 1
Total Assets NA 355 467 507 468
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 16 9 12 9
Current Portion Long-Term Debt NA 0 14 14 14
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 51 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 53 53 57
Total Current Liabilities NA 68 78 81 81
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 113 98 97 97
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 335 327 241
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 503 521 516 430
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 7 7 7 7
Capital Surplus NA 1,181 1,008 1,008 1,008
Retained Earnings NA -1,335 -1,235 -1,187 -1,140
Other Equity NA 0 166 164 163
Treasury Stock NA 1 1 1 1
Total Shareholder's Equity NA -148 -54 -9 38
Total Liabilities & Shareholder's Equity NA 355 467 507 468
Total Common Equity 0 -148 -54 -9 38
Shares Outstanding 82.50 76.80 76.80 76.80 76.80
Book Value Per Share 0.00 -1.93 -0.71 -0.11 0.49